Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: Novel biaryl indazoles as P2/P2' substituents

被引：62

作者：

Patel, M ^{[1
]}

Rodgers, JD ^{[1
]}

McHugh, RJ ^{[1
]}

Johnson, BL ^{[1
]}

Cordova, BC ^{[1
]}

Klabe, RM ^{[1
]}

Bacheler, LT ^{[1
]}

Erickson-Viitanen, S ^{[1
]}

Ko, SS ^{[1
]}

机构：

[1] DuPont Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 1999年 / 9卷 / 22期

关键词：

D O I：

10.1016/S0960-894X(99)00564-8

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The preparation of unsymmetrical cyclic ureas bearing novel biaryl indazoles as P2/P2' substituents was undertaken, utilizing a Suzuki coupling reaction as the key step. Compound 6i was equipotent to the lead compound of the series SE063. (C) 1999 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.

引用

页码：3217 / 3220

页数：4

共 15 条

[1] AN ASSAY FOR HIV RNA IN INFECTED CELL LYSATES, AND ITS USE FOR THE RAPID EVALUATION OF ANTIVIRAL EFFICACY [J].

BACHELER, LT ;

PAUL, M ;

OTTO, MJ ;

JADHAV, PK ;

STONE, BA ;

MILLER, JA .

ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1994, 5 (02) :111-121

[2]

BAIOCCHI L, 1978, SYNTHESIS-STUTTGART, P633

[3] Suzuki-type cross-coupling reaction of 3-iodoindazoles with aryl boronic acids: a general and flexible route to 3-arylindazoles [J].

Collot, V ;

Dallemagne, P ;

Bovy, PR ;

Rault, S .

TETRAHEDRON, 1999, 55 (22) :6917-6922

[4] Nonsymmetric P2/P2′ cyclic urea HIV protease inhibitors.: Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues [J].

De Lucca, GV ;

Kim, UT ;

Liang, J ;

Cordova, B ;

Klabe, RM ;

Garber, S ;

Bacheler, LT ;

Lam, GN ;

Wright, MR ;

Logue, KA ;

Erickson-Viitanen, S ;

Ko, SS ;

Trainor, GL .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (13) :2411-2423

[5] POTENCY AND SELECTIVITY OF INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE BY A SMALL NONPEPTIDE C4 CYCLIC UREA, DMP-323 [J].

ERICKSONVIITANEN, S ;

KLABE, RM ;

CAWOOD, PG ;

ONEAL, PL ;

MEEK, JL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) :1628-1634

[6] Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV [J].

Jadhav, PK ;

Ala, P ;

Woerner, FJ ;

Chang, CH ;

Garber, SS ;

Anton, ED ;

Bacheler, LT .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (02) :181-191

[7] PALLADIUM-CATALYZED CROSS-COUPLING REACTIONS OF ORGANOBORON COMPOUNDS [J].

MIYAURA, N ;

SUZUKI, A .

CHEMICAL REVIEWS, 1995, 95 (07) :2457-2483

[8]

RITTER K, 1993, SYNTHESIS-STUTTGART, P735

[9] Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors [J].

Rodgers, JD ;

Lam, PYS ;

Johnson, BL ;

Wang, HS ;

Ko, SS ;

Seitz, SP ;

Trainor, GL ;

Anderson, PS ;

Klabe, RM ;

Bacheler, LT ;

Cordova, B ;

Garber, S ;

Reid, C ;

Wright, MR ;

Chang, CH ;

Erickson-Viitanen, S .

CHEMISTRY & BIOLOGY, 1998, 5 (10) :597-608

[10] Potent cyclic urea HIV protease inhibitors with benzofused heterocycles as P2/P2' groups [J].

Rodgers, JD ;

Johnson, BL ;

Wang, HS ;

Greenberg, RA ;

EricksonViitanen, S ;

Klabe, RM ;

Cordova, BC ;

Rayner, MM ;

Lam, GN ;

Chang, CH .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (24) :2919-2924

← 1 2 →